Business Description
Vistin Pharma ASA
ISIN : NO0010734122
Total Employee Number:
77Compare
Compare
Traded in other countries / regions
VISTN.Norway0RAM.UKVP4.GermanyVISTINo.Sweden IPO Date
2015-08-26Description
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.51 | |||||
Equity-to-Asset | 0.74 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | 0.12 | |||||
Interest Coverage | 5.95 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 7.39 | |||||
Beneish M-Score | -1.85 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 16.3 | |||||
3-Year EBITDA Growth Rate | 142.6 | |||||
3-Year Book Growth Rate | 6.3 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 2.38 | |||||
9-Day RSI | 9.37 | |||||
14-Day RSI | 15.29 | |||||
3-1 Month Momentum % | -11.06 | |||||
6-1 Month Momentum % | -5.41 | |||||
12-1 Month Momentum % | -18.95 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.49 | |||||
Quick Ratio | 1.52 | |||||
Cash Ratio | 0.1 | |||||
Days Inventory | 218.17 | |||||
Days Sales Outstanding | 77.13 | |||||
Days Payable | 57.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 5.26 | |||||
Dividend Payout Ratio | 0.62 | |||||
Forward Dividend Yield % | 11.84 | |||||
5-Year Yield-on-Cost % | 5.26 | |||||
Shareholder Yield % | 5.72 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 67.61 | |||||
Operating Margin % | 18.76 | |||||
Net Margin % | 16.25 | |||||
EBITDA Margin % | 29.56 | |||||
FCF Margin % | 18.36 | |||||
OCF Margin % | 22.18 | |||||
ROE % | 21.86 | |||||
ROA % | 16.14 | |||||
ROIC % | 15.69 | |||||
3-Year ROIIC % | 1702.56 | |||||
ROC (Joel Greenblatt) % | 31.5 | |||||
ROCE % | 29.73 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 12.22 | |||||
PE Ratio without NRI | 12.04 | |||||
Shiller PE Ratio | 25.5 | |||||
Price-to-Owner-Earnings | 18.17 | |||||
PS Ratio | 1.98 | |||||
PB Ratio | 2.67 | |||||
Price-to-Tangible-Book | 2.67 | |||||
Price-to-Free-Cash-Flow | 10.79 | |||||
Price-to-Operating-Cash-Flow | 8.93 | |||||
EV-to-EBIT | 8.33 | |||||
EV-to-EBITDA | 6.76 | |||||
EV-to-Revenue | 2 | |||||
EV-to-FCF | 10.89 | |||||
Price-to-GF-Value | 0.81 | |||||
Price-to-Projected-FCF | 7.12 | |||||
Price-to-Median-PS-Value | 0.85 | |||||
Price-to-Graham-Number | 1.2 | |||||
| Price-to-Net-Current-Asset-Value | 9.74 | |||||
Earnings Yield (Greenblatt) % | 12 | |||||
FCF Yield % | 9.27 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vistin Pharma ASA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 432.001 | ||
| EPS (TTM) (kr) | 1.58 | ||
| Beta | 0.3976 | ||
| 3-Year Sharpe Ratio | -0.35 | ||
| 3-Year Sortino Ratio | -0.49 | ||
| Volatility % | 17.97 | ||
| 14-Day RSI | 15.29 | ||
| 14-Day ATR (kr) | 0.110163 | ||
| 20-Day SMA (kr) | 19.9475 | ||
| 12-1 Month Momentum % | -18.95 | ||
| 52-Week Range (kr) | 19 - 24.8 | ||
| Shares Outstanding (Mil) | 44.34 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vistin Pharma ASA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vistin Pharma ASA Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-12 08:30 | In 174 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-12 | In 173 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-29 | In 67 days | ||
| Third quarter earnings results for 2026 | 2026-10-29 | In 67 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-20 | 20.00 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-08-20 | 20.00 (+0.00%) | ||
| NOK 1.000000 Cash Dividend | 2026-05-22 | 22.60 (+0.00%) | ||
| General meeting for 2025 | 2026-05-20 13:00 | 22.60 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-04-24 08:30 | 21.50 (+0.00%) | ||
| Annual report for 2025 | 2026-04-24 | 21.50 (+0.00%) |
Show
Entries
Vistin Pharma ASA Frequently Asked Questions
What is Vistin Pharma ASA(LTS:0RAM)'s stock price today?
The current price of LTS:0RAM is kr19.00. The 52 week high of LTS:0RAM is kr24.80 and 52 week low is kr19.00.
When is next earnings date of Vistin Pharma ASA(LTS:0RAM)?
The next earnings date of Vistin Pharma ASA(LTS:0RAM) is 2026-10-29.
Does Vistin Pharma ASA(LTS:0RAM) pay dividends? If so, how much?
The Dividend Yield %  of Vistin Pharma ASA(LTS:0RAM) is 5.26% (As of Today), Highest Dividend Payout Ratio of Vistin Pharma ASA(LTS:0RAM) was 3.06. The lowest was 0.62. And the median was 1.06. The  Forward Dividend Yield % of Vistin Pharma ASA(LTS:0RAM) is 11.84%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Vistin Pharma ASA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers